Corporate Officers

Mitchel Sayare, Ph.D. Chairman, President and CEO

Mitchel Sayare is Chairman, President, and Chief Executive Officer of ImmunoGen. Before joining ImmunoGen in 1986, Dr. Sayare was Vice President for Development at Xenogen, Inc., a biotechnology company specializing in monoclonal antibody-based diagnostic systems for cancer. Prior to joining Xenogen, he was Assistant Professor of Biophysics and Biochemistry at the University of Connecticut. Dr. Sayare serves on the board of the biotechnology industry association BIO, of the public company ImmuCell Corporation, and of a number of private companies. He holds a doctorate in Biochemistry from Temple University School of Medicine.

Daniel M. Junius Chief Financial Officer and Executive Vice President, Finance

Daniel Junius joined ImmunoGen in May 2005 as Chief Financial Officer (CFO) and Senior Vice President, Finance and was promoted to Executive Vice President, Finance in July 2006. Mr. Junius was Executive Vice President and CFO of New England Business Service, Inc. (NEBS) from 1998 until its acquisition by Deluxe Corporation in 2004. Prior to NEBS, he was Vice President and CFO of Nashua Corporation. He joined Nashua Corporation in 1984 and held financial management positions of increasing responsibility before becoming CFO in 1996. Mr. Junius holds a Masters in Management from Northwestern University’s Kellogg School of Management.

John M. Lambert, Ph.D. Senior Vice President, Research and Development and Chief Scientific Officer

John M. Lambert joined ImmunoGen in 1987. He served the Company previously as Senior Director of Research and then as Vice President of Research. Prior to his tenure with ImmunoGen, he was Assistant Professor of Pathology at the Dana-Farber Cancer Institute in Boston, Massachusetts, where he worked on the research program supported by ImmunoGen. Dr. Lambert received his Ph.D. in Biochemistry from Cambridge University in England.

Craig Barrows Vice President, General Counsel and Secretary

Craig Barrows joined ImmunoGen in October 2007 with over twenty years of legal experience – thirteen as chief corporate legal officer – and a strong transactional background. Mr. Barrows was general counsel of M/A-COM, Inc. from 1994 until the company was acquired in 1996, general counsel and secretary of Media 100 Inc. before he joined New England Business Service, Inc. (NEBS) in 1998, and vice president, general counsel and secretary of NEBS until the company was acquired in 2004. Most recently, Mr. Barrows was vice president, general counsel and assistant secretary of Mercury Computer Systems, Inc. Before transitioning to in-house counsel, Mr. Barrows focused on corporate and securities law at Skadden, Arps, Slate, Meagher & Flom. He earned his undergraduate degree at the University of Chicago and his law degree at Fordham University School of Law.

John Tagliamonte Vice President, Business Development

John Tagliamonte joined ImmunoGen in November 2007 as Vice President, Business Development. He was most recently Senior Director of Strategy and Corporate Development at Millipore Corporation, where he led strategy, M&A execution and integration, licensing and alliances. Prior to joining Millipore in 2005, Mr. Tagliamonte served as Vice President of Commercial Operations at Laureate Pharma, a private life sciences company based in Princeton, NJ. Previously, he was Director of Business Development and Strategic Planning of the Ortho-Clinical Diagnostics unit of Johnson & Johnson. Mr. Tagliamonte held additional positions in business development and product management at Perkin Elmer and Bio-Rad Laboratories and has held research positions at Collaborative Research and Dana-Farber Cancer Institute. He currently serves on the advisory board of directors at BioHelix, a molecular diagnostics firm. Mr. Tagliamonte received his M.B.A. from Boston College and a B.S. in Molecular Cell Biology from Tufts University.